Literature DB >> 33596893

Targeting Nrf2 may reverse the drug resistance in ovarian cancer.

Danjie Li1, Xiaoling Hong1, Feijie Zhao1, Xinxin Ci2, Songling Zhang3.   

Abstract

BACKGROUND: Acquired resistance to therapeutic drugs has become an important issue in treating ovarian cancer. Studies have shown that the prevalent chemotherapy resistance (cisplatin, paclitaxel etc.) for ovarian cancer occurs partly because of decreased production of reactive oxygen species within the mitochondria of ovarian cancer cells. MAIN BODY: Nuclear erythroid-related factor-2 (Nrf2) mainly controls the regulation of transcription of genes through the Keap1-Nrf2-ARE signaling pathway and protects cells by fighting oxidative stress and defending against harmful substances. This protective effect is reflected in the promotion of tumor cell growth and their resistance to chemotherapy drugs. Therefore, inhibition of the Nrf2 pathway may reverse drug resistance. In this review, we describe the functions of Nrf2 in drug resistance based on Nrf2-associated signaling pathways determined in previous studies.
CONCLUSIONS: Further studies on the relevant mechanisms of Nrf2 may help improve the outcomes of ovarian cancer therapy.

Entities:  

Keywords:  Drug resistance; Nrf2; Ovarian cancer; Reactive oxidative stress

Year:  2021        PMID： 33596893      PMCID： PMC7890806          DOI： 10.1186/s12935-021-01822-1

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN： 1475-2867            Impact factor:   5.722


  102 in total

1.  Effect of stable inhibition of NRF2 on doxorubicin sensitivity in human ovarian carcinoma OV90 cells.

Authors:  Sarala Manandhar; Sangwhan Lee; Mi-Kyoung Kwak
Journal:  Arch Pharm Res       Date:  2010-05-29       Impact factor: 4.946

2.  Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.

Authors:  Phui-Ly Liew; Chun-Sen Hsu; Wei-Min Liu; Yu-Chieh Lee; Yi-Chih Lee; Chi-Long Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth.

Authors:  Tsutomu Ohta; Kumiko Iijima; Mamiko Miyamoto; Izumi Nakahara; Hiroshi Tanaka; Makiko Ohtsuji; Takafumi Suzuki; Akira Kobayashi; Jun Yokota; Tokuki Sakiyama; Tatsuhiro Shibata; Masayuki Yamamoto; Setsuo Hirohashi
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

4.  Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway.

Authors:  Ai-Mei Gao; Zun-Ping Ke; Jia-Ning Wang; Jian-Ye Yang; Shi-You Chen; Hui Chen
Journal:  Carcinogenesis       Date:  2013-04-04       Impact factor: 4.944

5.  Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.

Authors:  Daiha Shin; Eun Hye Kim; Jaewang Lee; Jong-Lyel Roh
Journal:  Free Radic Biol Med       Date:  2018-10-16       Impact factor: 7.376

6.  Juvenile granulosa cell tumors: immunoreactivity for CD99 and Fli-1 and EWSR1 translocation status: a study of 11 cases.

Authors:  Elke A Jarboe; Sharon L Hirschowitz; Katherine B Geiersbach; Michelle L Wallander; Sheryl R Tripp; Lester J Layfield
Journal:  Int J Gynecol Pathol       Date:  2014-01       Impact factor: 2.762

7.  Sustained production of ROS triggers compensatory proliferation and is required for regeneration to proceed.

Authors:  Carole Gauron; Christine Rampon; Mohamed Bouzaffour; Eliane Ipendey; Jérémie Teillon; Michel Volovitch; Sophie Vriz
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

8.  Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.

Authors:  Rodrigo Romero; Volkan I Sayin; Shawn M Davidson; Matthew R Bauer; Simranjit X Singh; Sarah E LeBoeuf; Triantafyllia R Karakousi; Donald C Ellis; Arjun Bhutkar; Francisco J Sánchez-Rivera; Lakshmipriya Subbaraj; Britney Martinez; Roderick T Bronson; Justin R Prigge; Edward E Schmidt; Craig J Thomas; Chandra Goparaju; Angela Davies; Igor Dolgalev; Adriana Heguy; Viola Allaj; John T Poirier; Andre L Moreira; Charles M Rudin; Harvey I Pass; Matthew G Vander Heiden; Tyler Jacks; Thales Papagiannakopoulos
Journal:  Nat Med       Date:  2017-10-02       Impact factor: 53.440

9.  H-Ferritin Affects Cisplatin-Induced Cytotoxicity in Ovarian Cancer Cells through the Modulation of ROS.

Authors:  Alessandro Salatino; Ilenia Aversa; Anna Martina Battaglia; Alessandro Sacco; Anna Di Vito; Gianluca Santamaria; Roberta Chirillo; Pierangelo Veltri; Giuseppe Tradigo; Annalisa Di Cello; Roberta Venturella; Flavia Biamonte; Francesco Costanzo
Journal:  Oxid Med Cell Longev       Date:  2019-10-31       Impact factor: 6.543

10.  p62 Suppressed VK3-induced Oxidative Damage Through Keap1/Nrf2 Pathway In Human Ovarian Cancer Cells.

Authors:  Mei-Hui Xia; Xiao-Yu Yan; Lei Zhou; Long Xu; Li-Chao Zhang; Hao-Wei Yi; Jing Su
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207
View more
  7 in total

1.  Clinicopathological significance and underlying molecular mechanism of downregulation of basonuclin 1 expression in ovarian carcinoma.

Authors:  Zi-Qian Liang; Lu-Yang Zhong; Jie Li; Jin-Hai Shen; Xin-Yue Tu; Zheng-Hong Zhong; Jing-Jing Zeng; Jun-Hong Chen; Zhu-Xin Wei; Yi-Wu Dang; Su-Ning Huang; Gang Chen
Journal:  Exp Biol Med (Maywood)       Date:  2021-10-13

2.  Systematic interrogation of mutation groupings reveals divergent downstream expression programs within key cancer genes.

Authors:  Michal R Grzadkowski; Hannah D Holly; Julia Somers; Emek Demir
Journal:  BMC Bioinformatics       Date:  2021-05-06       Impact factor: 3.307

Review 3.  The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis.

Authors:  Ana Luiza Drumond-Bock; Magdalena Bieniasz
Journal:  Mol Cancer       Date:  2021-11-10       Impact factor: 27.401

Review 4.  Insights into the Role of Oxidative Stress in Ovarian Cancer.

Authors:  Dan-Ni Ding; Liang-Zhen Xie; Ying Shen; Jia Li; Ying Guo; Yang Fu; Fang-Yuan Liu; Feng-Juan Han
Journal:  Oxid Med Cell Longev       Date:  2021-10-07       Impact factor: 6.543

Review 5.  Oxidative Stress and Cancer Heterogeneity Orchestrate NRF2 Roles Relevant for Therapy Response.

Authors:  Koraljka Gall Trošelj; Marko Tomljanović; Morana Jaganjac; Tanja Matijević Glavan; Ana Čipak Gašparović; Lidija Milković; Suzana Borović Šunjić; Brigitta Buttari; Elisabetta Profumo; Sarmistha Saha; Luciano Saso; Neven Žarković
Journal:  Molecules       Date:  2022-02-22       Impact factor: 4.411

Review 6.  Revisiting therapeutic strategies for ovarian cancer by focusing on redox homeostasis.

Authors:  Hiroshi Kobayashi; Shogo Imanaka; Hiroshi Shigetomi
Journal:  Oncol Lett       Date:  2022-01-11       Impact factor: 2.967

7.  Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.

Authors:  Juan Zhang; Hong-Xi Xu; William Chi Shing Cho; Wah Cheuk; Yang Li; Qiong-Hui Huang; Wen Yang; Yan-Fang Xian; Zhi-Xiu Lin
Journal:  J Exp Clin Cancer Res       Date:  2022-03-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.